Brainstorm Cell Therapeutics (NASDAQ: BCLI) reported Q1 EPS of ($0.10), $0.15 better than the analyst estimate of ($0.25).

For earnings history and earnings-related data on Brainstorm Cell Therapeutics (BCLI) click here.